Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA:600513)
China · Delayed Price · Currency is CNY 21.89
+1.32 (6.42%)
Apr 29, 2026, 3:00 PM CST
SHA:600513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,712 | 2,155 | 2,153 | 1,939 | 1,646 |
Other Revenue | - | 5.67 | 21.46 | 15.97 | - |
| 2,712 | 2,160 | 2,174 | 1,955 | 1,646 | |
Revenue Growth (YoY) | 25.52% | -0.63% | 11.20% | 18.80% | 18.74% |
Cost of Revenue | 1,768 | 1,099 | 1,130 | 912.62 | 748.86 |
Gross Profit | 943.63 | 1,062 | 1,044 | 1,043 | 896.95 |
Selling, General & Admin | 685.18 | 758.72 | 711.12 | 721.05 | 643.6 |
Research & Development | 205.27 | 154.59 | 132.14 | 92.44 | 66.47 |
Other Operating Expenses | 3.78 | 16.67 | 18.21 | 18.36 | 15.36 |
Operating Expenses | 894.23 | 936.7 | 864.04 | 839.7 | 725.43 |
Operating Income | 49.4 | 124.81 | 179.96 | 202.84 | 171.52 |
Interest Expense | - | -24.95 | -26.69 | -25.18 | -19.1 |
Interest & Investment Income | - | 0.68 | 1.33 | 2.74 | 1.94 |
Currency Exchange Gain (Loss) | - | 0.63 | 0.23 | 2.31 | -0.79 |
Other Non Operating Income (Expenses) | -115.91 | -1.25 | -1.5 | -1.11 | 0.65 |
EBT Excluding Unusual Items | -66.51 | 99.92 | 153.33 | 181.6 | 154.22 |
Gain (Loss) on Sale of Investments | -10.16 | -10.59 | -0.42 | -2.86 | -1.5 |
Gain (Loss) on Sale of Assets | -0.08 | 34.92 | 7.89 | -0.03 | -0.06 |
Asset Writedown | -10.86 | - | - | - | - |
Other Unusual Items | - | 6.18 | 14.23 | 10.35 | 6.91 |
Pretax Income | -87.61 | 130.43 | 175.03 | 189.05 | 159.56 |
Income Tax Expense | -3.45 | 24.01 | 23.69 | 22.61 | 19.66 |
Earnings From Continuing Operations | -84.15 | 106.41 | 151.34 | 166.44 | 139.9 |
Minority Interest in Earnings | -14.18 | -22.25 | -16.33 | -25.07 | -21.06 |
Net Income | -98.33 | 84.16 | 135.01 | 141.37 | 118.84 |
Net Income to Common | -98.33 | 84.16 | 135.01 | 141.37 | 118.84 |
Net Income Growth | - | -37.66% | -4.50% | 18.96% | 15.38% |
Shares Outstanding (Basic) | 289 | 290 | 287 | 289 | 290 |
Shares Outstanding (Diluted) | 289 | 290 | 287 | 289 | 290 |
Shares Change (YoY) | -0.34% | 1.03% | -0.44% | -0.46% | 1.31% |
EPS (Basic) | -0.34 | 0.29 | 0.47 | 0.49 | 0.41 |
EPS (Diluted) | -0.34 | 0.29 | 0.47 | 0.49 | 0.41 |
EPS Growth | - | -38.30% | -4.08% | 19.51% | 13.89% |
Free Cash Flow | -285.87 | -174.08 | -39.96 | -93.09 | -33.77 |
Free Cash Flow Per Share | -0.99 | -0.60 | -0.14 | -0.32 | -0.12 |
Dividend Per Share | - | 0.089 | 0.150 | 0.150 | 0.125 |
Dividend Growth | - | -40.67% | - | 20.00% | 15.74% |
Gross Margin | 34.80% | 49.13% | 48.02% | 53.32% | 54.50% |
Operating Margin | 1.82% | 5.78% | 8.28% | 10.37% | 10.42% |
Profit Margin | -3.63% | 3.90% | 6.21% | 7.23% | 7.22% |
Free Cash Flow Margin | -10.54% | -8.06% | -1.84% | -4.76% | -2.05% |
EBITDA | 146.44 | 184.39 | 235.75 | 243.65 | 199.57 |
EBITDA Margin | 5.40% | 8.54% | 10.84% | 12.46% | 12.13% |
D&A For EBITDA | 97.04 | 59.59 | 55.79 | 40.81 | 28.05 |
EBIT | 49.4 | 124.81 | 179.96 | 202.84 | 171.52 |
EBIT Margin | 1.82% | 5.78% | 8.28% | 10.37% | 10.42% |
Effective Tax Rate | - | 18.41% | 13.54% | 11.96% | 12.32% |
Revenue as Reported | - | 2,160 | 2,174 | 1,955 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.